Research programme: Alzheimer's disease antibody therapeutics - Alector/Janssen

Drug Profile

Research programme: Alzheimer's disease antibody therapeutics - Alector/Janssen

Alternative Names: Alzheimer's disease antibody therapeutics - Alector/Johnson & Johnson

Latest Information Update: 13 Mar 2014

Price : $50

At a glance

  • Originator Alector
  • Developer Alector; Janssen Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease

Most Recent Events

  • 10 Mar 2014 Early research in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top